Interactions between the CB1 receptor agonist Delta 9-THC and the CB1 receptor antagonist SR-141716 in rats: open-field revisited.

Pharmacol Biochem Behav

Temple University, Department of Psychology, 265-67 Weiss Hall, 1701 North 13th Street, Philadelphia, PA 19122, USA.

Published: November 2002

This study examined the effects of Delta(9)-tetrahydrocannabinol (Delta(9)-THC) and the CB1 antagonist SR-141716 on open-field behaviors in male Sprague-Dawley rats. Animals were examined after administration of Delta(9)-THC alone (dose range: 0.3-5.6 mg/kg), SR-141716 alone (dose range: 1-5.6 mg/kg) and the two drugs in combination; injections were given intraperitoneally 30 min prior to testing. There was a dose-related suppression of ambulation (horizontal activity) and rearing (vertical activity) after Delta(9)-THC administration. Co-administration of SR-141716 counteracted this suppression; however, antagonism was only partial for rearing. Interestingly, 1 mg/kg SR-141716 was as effective as 3 and 5.6 mg/kg SR-141716 in this antagonist action. Increasing doses of Delta(9)-THC produced an increase in circling behavior; latency to leave the starting area in the center of the field was significantly elevated by 5.6 mg/kg Delta(9)-THC. Those effects were completely blocked by SR-141716. Grooming and scratching showed a dose-related increase following administration of SR-141716 (1-5.6 mg/kg), which were only partially blocked by co-administration of Delta(9)-THC (3 and 5.6 mg/kg). When given alone, only the highest dose of SR-141716 (5.6 mg/kg) depressed ambulation; rearing and latency were not significantly changed, and circling was absent. Differences in the number of vocalizations, urination and defecation generally did not differ clearly among the treatment conditions. These results may show that SR-141716 is acting as (i) an inverse agonist and/or (ii) that the endogenous cannabinoid system is tonically active under certain conditions.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0091-3057(02)00938-3DOI Listing

Publication Analysis

Top Keywords

mg/kg sr-141716
12
sr-141716
10
cb1 receptor
8
antagonist sr-141716
8
dose range
8
mg/kg
8
1-56 mg/kg
8
delta9-thc
6
interactions cb1
4
receptor agonist
4

Similar Publications

Modulation of the endocannabinoid system by (S)-ketamine in an animal model of depression.

Pharmacol Res

January 2025

Department of Biomedicine, Aarhus University, Denmark; Translational Neuropsychiatry Unit, Aarhus University, Denmark. Electronic address:

Ketamine (KET) is recognized as rapid-acting antidepressant, but its mechanisms of action remain elusive. Considering the role of endocannabinoids (eCB) in stress and depression, we investigated if S-KET antidepressant effects involve the regulation of the eCB system using an established rat model of depression based on selective breeding: the Flinders Sensitive Line (FSL) and their controls, the Flinders Resistant Line (FRL). S-KET (15 mg/kg) effects were assessed in rats exposed to the open field and forced swimming test (FST), followed by analysis of the eCB signaling in the rat prefrontal cortex (PFC), a brain region involved in depression neurobiology.

View Article and Find Full Text PDF

The CB1 antagonist Rimonabant improves muscle regeneration and remodels the inflammatory and endocannabinoid profile upon injury in male mice.

Life Sci

January 2025

Exercise Physiology Research Group, Department of Movement Sciences, KU Leuven, Tervuursevest 101, 3001 Leuven, Belgium. Electronic address:

Skeletal muscle regeneration upon injury requires timely activation of inflammatory, myogenic, fibrotic, apoptotic and anabolic systems. Optimization of these features might improve the recovery process. Whereas recent data indicate that the endocannabinoid system, and more particularly cannabinoid receptor 1 (CB1) antagonism, is involved in the regulation of inflammatory, myogenic, fibrotic, apoptotic and anabolic pathways, it was never studied whether CB1 antagonism can improve muscle regeneration.

View Article and Find Full Text PDF

A Sex-Dependent Cannabinoid CB1 Receptor Role in Circadian Tearing of the Mouse.

Invest Ophthalmol Vis Sci

December 2024

The Gill Institute for Neuroscience, Indiana University, Bloomington, Indiana, United States.

Purpose: We have shown that cannabinoid CB1 receptors regulate both salivation and tearing, but for tearing, this regulation is sex dependent with opposing effects by sex. We investigated a potential interplay of circadian and cannabinoid regulation of tearing.

Methods: We measured cannabinoid and circadian regulation of tearing in CD1 strain mice as well as CB1 receptor protein expression using immunohistochemistry.

View Article and Find Full Text PDF

Functional Adaptation in the Brain Habenulo-Mesencephalic Pathway During Cannabinoid Withdrawal.

Cells

November 2024

Neuroscience Institute, Section of Cagliari, National Research Council of Italy, Cittadella Universitaria di Monserrato, I-09042 Cagliari, Italy.

The mesolimbic reward system originating from dopamine neurons in the ventral tegmental area (VTA) of the midbrain shows a profound reduction in function during cannabinoid withdrawal. This condition may underlie aversive states that lead to compulsive drug seeking and relapse. The lateral habenula (LHb) exerts negative control over the VTA via the GABA rostromedial tegmental nucleus (RMTg), representing a potential convergence point for drug-induced opponent processes.

View Article and Find Full Text PDF

Rationale: The newly emerging synthetic cannabinoids (SCs) 5F-EDMB-PICA, CUMYL-PEGACLONE, and NM-2201 have been observed to produce effects by activating cannabinoid type 1 (CB1) receptors. Nevertheless, the pharmacological effects and potential for abuse of these three substances remain to be studied. These substances have yet to be regulated in many countries.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!